Results from a large post-marketing safety surveillance study in the Republic of Korea with a quadrivalent meningococcal CRM-conjugate vaccine in individuals aged 2 months–55 years

The quadrivalent meningococcal conjugate vaccine MenACWY-CRM is approved in the Republic of Korea for use in individuals from 2 months of age. This single-arm, open-label, observational, multicenter, post-marketing study (NCT01766206) assessed the safety of MenACWY-CRM vaccine administered according...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Byung Wook, Jung, Hye Lim, Byeon, Yoon Seob, Han, Dong Ki, Jeong, Nak Yeong, Curina, Carlo, Moraschini, Luca, Kim, Sung Jin, Bhusal, Chiranjiwi, Pellegrini, Michele, Miao, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482729/
https://www.ncbi.nlm.nih.gov/pubmed/31634044
http://dx.doi.org/10.1080/21645515.2019.1670125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482729/
https://www.ncbi.nlm.nih.gov/pubmed/31634044
http://dx.doi.org/10.1080/21645515.2019.1670125

Ejemplares similares